

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2018
Document Type: USP Monographs
DocId: GUID-E23CDFA9-79C3-45BB-9B33-009E5981F004_3_en-US
DOI: https://doi.org/10.31003/USPNF_M61730_03_01
DOI Ref: u9736

© 2025 USPC
Do not distribute

Penicillin G Sodium for Injection

DEFINITION

Penicillin G Sodium for Injection is sterile Penicillin G Sodium or a sterile mixture of Penicillin G Sodium and NLT 4.0% and NMT 5.0% of Sodium Citrate, of which NMT 0.15% may be replaced by Citric Acid. It contains NLT 90.0% and NMT 120.0% of the labeled amount of penicillin G. In addition, where it contains Sodium Citrate, it has a potency of NLT 1420 and NMT 1667 Penicillin G Units/mg.

IDENTIFICATION

• A. THIN-LAYER CHROMATOGRAPHY

Solution A: Acetone, 0.1 M citric acid, and 0.1 M sodium citrate (2:1:1)

Standard solution: Prepare a solution containing the equivalent of 12,000 Penicillin G Units/mL from [USP Penicillin G Potassium RS](#) in *Solution A*.

Sample solution: Nominally 12,000 Penicillin G Units/mL from Penicillin G Sodium for Injection in *Solution A*

Chromatographic system

(See [Chromatography \(621\), Thin-Layer Chromatography](#).)

Adsorbent: 0.25-mm layer of chromatographic silica gel mixture

Application volume: 20 μ L

Developing solvent system: Toluene, dioxane, and glacial acetic acid (90:25:4)

Spray reagent 1: Starch TS

Spray reagent 2: Iodine TS diluted 1 in 10 with water

Analysis

Samples: Standard solution and Sample solution

Place the plate in a suitable chromatographic chamber. Develop the chromatogram using the *Developing solvent system* until the solvent front has moved three-fourths of the length of the plate. Remove the plate from the chamber, mark the solvent front, and allow to air-dry. Spray the plate with *Spray reagent 1* followed by *Spray reagent 2*. Penicillin G appears as a white spot on a purple background.

Acceptance criteria: The R_F value of the penicillin G spot from the *Sample solution* corresponds to that from the *Standard solution*.

ASSAY

• PROCEDURE

Solution A: 0.01 M monobasic potassium phosphate

Mobile phase: Methanol and *Solution A* (40:60)

System suitability solution: 0.1 mg/mL each of [USP Penicillin G Potassium RS](#) and 2-phenylacetamide in water

Standard solution: 0.1 mg/mL of [USP Penicillin G Potassium RS](#) in water. Shake as needed to dissolve. This solution contains about 160 Penicillin G Units/mL.

Sample solution 1 (where it is represented as being in a single-dose container): Constitute Penicillin G Sodium for Injection as directed in the labeling. Withdraw all of the withdrawable contents, using a hypodermic needle and syringe, and dilute with water to obtain a solution containing nominally 160 Penicillin G Units/mL.

Sample solution 2 (where the label states the quantity of penicillin G in a given volume of constituted solution): Constitute Penicillin G Sodium for Injection as directed in the labeling. Dilute a suitable aliquot of the constituted solution with water to obtain a solution containing nominally 160 Penicillin G Units/mL.

Sample solution 3 (where it contains sodium citrate): Transfer about 50 mg of the Penicillin G Sodium for Injection to a 500-mL volumetric flask, add about 400 mL of water, and shake to dissolve. Dilute with water to volume, and mix.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm \times 10-cm; 5- μ m packing L1

Flow rate: 1 mL/min**Injection volume:** 10 μ L**System suitability****Samples:** System suitability solution and Standard solution

[NOTE—The relative retention times for 2-phenylacetamide and penicillin G are about 0.8 and 1.0, respectively.]

Suitability requirements**Resolution:** NLT 2.0 between 2-phenylacetamide and penicillin G, System suitability solution**Column efficiency:** NLT 1000 theoretical plates, Standard solution**Tailing factor:** NMT 2.0, Standard solution**Relative standard deviation:** NMT 2.0%, Standard solution**Analysis****Samples:** Standard solution and Sample solution 1, Sample solution 2, or Sample solution 3

Perform the Assay on 10 containers where it is represented as being in a single-dose container and, if necessary, on 10 containers where the label states the quantity of penicillin G in a given volume of constituted solution. Use the individual results to determine the *Uniformity of Dosage Units* and the average of the results as the Assay value.

Calculate the percentage of the labeled amount of penicillin G in the container or in the portion of constituted solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times 100$$

 r_U = peak response from Sample solution 1 or Sample solution 2 r_S = peak response from the Standard solution C_S = concentration of [USP Penicillin G Potassium RS](#) in the Standard solution (mg/mL) C_U = nominal concentration of Sample solution 1 or Sample solution 2 (Penicillin G Units/mL) P = potency of penicillin G in [USP Penicillin G Potassium RS](#) (Penicillin G Units/mg)

Calculate the potency, in Penicillin G Units/mg, in the portion of Penicillin G Sodium for Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P$$

 r_U = peak response from Sample solution 3 r_S = peak response from the Standard solution C_S = concentration of [USP Penicillin G Potassium RS](#) in the Standard solution (mg/mL) C_U = concentration of Penicillin G Sodium for Injection in Sample solution 3 (mg/mL) P = potency of penicillin G in [USP Penicillin G Potassium RS](#) (Penicillin G Units/mg)

Acceptance criteria: 90.0%–120.0% of the labeled amount of penicillin G. Where Penicillin G Sodium for Injection contains sodium citrate, it has a potency of NLT 1420 and NMT 1667 Penicillin G Units/mg.

PERFORMANCE TESTS

• [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements. Perform the Assay on 10 containers where it is represented as being in a single-dose container and, if necessary, on 10 containers where the label states the quantity of penicillin G in a given volume of constituted solution. Use the individual results to determine the *Uniformity of Dosage Units* and the average of the results as the Assay value.

SPECIFIC TESTS

• [INJECTIONS AND IMPLANTED DRUG PRODUCTS \(1\), Specific Tests, Completeness and clarity of solutions](#): At the time of use, it meets the requirements.

• [CRYSTALLINITY \(695\)](#): Meets the requirements

• [STERILITY TESTS \(71\)](#): It meets the requirements when tested as directed in [Test for Sterility of the Product to Be Examined, Membrane Filtration](#).

• [BACTERIAL ENDOTOXINS TEST \(85\)](#): It contains NMT 0.01 USP Endotoxin Units/100 Penicillin G Units.

• [pH \(791\)](#):

Sample solution: A solution containing 60 mg/mL

Acceptance criteria: 5.0–7.5. Where it is labeled as containing sodium citrate, the pH is between 6.0 and 7.5.

• [LOSS ON DRYING \(731\)](#):

Sample: 100 mg of Penicillin G Sodium for Injection

Analysis: Dry the Sample in a capillary-stoppered bottle under vacuum at a pressure NMT 5 mm of mercury at 60° for 3 h.

Acceptance criteria: NMT 1.5%

- **PARTICULATE MATTER IN INJECTIONS (788):** Meets the requirements for small-volume injections
- **LABELING (7), Labels and Labeling for Injectable Products:** Meets the requirements

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\), Injection Packaging, Packaging for constitution](#).
- **USP REFERENCE STANDARDS (11):**

[USP Penicillin G Potassium RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PENICILLIN G SODIUM FOR INJECTION	Ying Han Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	BIO42020 Biologics Monographs 4 - Antibiotics

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 30(1)

Current DocID: [GUID-E23CDFA9-79C3-45BB-9B33-009E5981F004_3_en-US](#)

Previous DocID: [GUID-E23CDFA9-79C3-45BB-9B33-009E5981F004_1_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M61730_03_01

DOI ref: [u9736](#)